Tag: Pediatric brain tumor breakthrough 2024

Home / Pediatric brain tumor breakthrough 2024

Categories

Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma

April 2024: The Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.). This approval is specifically for patients aged 6 months and ...
pediatric-brain-tumor-breakthrough-2024

Scan the code